BRCA1 and cancer: Since 2018, patients relapsing after previous chemotherapy in the neoadjuvant, adjuvant, or metastatic setting are eligible to treatment with PARP inhibitors such as olaparib and talazoparib, inducing synthetic lethality in BRCA1 or BRCA2 cancers [21,25,26,27].